Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Medullary 9Lung Neoplasms 8Thyroid Neoplasms 7Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Stomach Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Gliosarcoma 2Glioblastoma 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Urinary Bladder Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Oligodendroglioma 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1

Interventions

Magnetic Resonance Spectroscopy 5lenvatinib 3cabozantinib 3Sunitinib 3Iodine-131 3trametinib 2selpercatinib 2dabrafenib 2Sorafenib 2Fluorodeoxyglucose F18 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vandetanib 1tremelimumab 1tovorafenib 1tanespimycin 1romidepsin 1pralsetinib 1pembrolizumab 1omipalisib 1durvalumab 1copanlisib 1cediranib 1alectinib 1aflibercept 1Vorinostat 1Vemurafenib 1Thyrotropin Alfa 1Thyroidectomy 1Thyroid (USP) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Cancer, Papillary × vandetanib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡